NCT01824875 2026-02-25
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
Clinical Trials
21 trialsNCT01525082 2024-02-06
Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors
Stanford University
Phase 2 Completed
NCT00427349 2023-07-05
AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT02031536 2023-06-29
Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery
Eastern Cooperative Oncology Group
Phase 2 Terminated
NCT04915144 2023-02-21
177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs
British Columbia Cancer Agency
Phase 2 Withdrawn
NCT02259725 2021-12-15
Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors
University of Southern California
Phase 2 Completed
NCT02108782 2017-07-19
Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors
Academic and Community Cancer Research United
Phase 2 Withdrawn
NCT00001191 2017-07-02
The Use of Oral Omeprazole and Intravenous Pantoprazole in Patients With Hypersecretion of Gastric Acid
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00050349 2017-03-01
EPO906 in Carcinoid and Other Neuroendocrine Tumors
Novartis
Phase 2 Completed
NCT02273752 2017-02-03
Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer
Emory University
Phase 2 Terminated
NCT00869050 2016-07-25
Capecitabine and Temozolomide for Neuroendocrine Cancers
Columbia University
Phase 2 Completed
NCT00416767 2016-05-30
Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
NCT00227773 2015-10-08
Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors
Eastern Cooperative Oncology Group
Phase 2 Withdrawn
NCT00131911 2014-11-17
Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
National Cancer Institute (NCI)
Phase 2 Completed
NCT00602082 2013-08-07
Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors
National Cancer Institute (NCI)
Phase 2 Completed
NCT00027638 2013-06-18
Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00075439 2013-06-04
Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
National Cancer Institute (NCI)
Phase 2 Completed
NCT00084461 2013-06-04
Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00017199 2013-01-31
PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors
National Cancer Institute (NCI)
Phase 2 Completed
NCT00466856 2012-05-18
Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors
Vanderbilt-Ingram Cancer Center
Phase 2 Terminated
NCT00001165 2008-03-04
Combination Chemotherapy in Patients With Zollinger-Ellison Syndrome and Tumors of the Pancreas
National Institutes of Health Clinical Center (CC)
Phase 2 Completed